- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.01. | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.01. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 23.12.25 | Vor Biopharma: Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors | 4 | GlobeNewswire (USA) | ||
| 18.12.25 | Vor Biopharma Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.12.25 | Vor Biopharma: TD Cowen startet mit Kaufempfehlung und verweist auf Telitacicept-Potenzial | 11 | Investing.com Deutsch | ||
| 17.12.25 | Vor Biopharma stock initiated with Buy rating at TD Cowen on promising telitacicept potential | 1 | Investing.com | ||
| 15.12.25 | Vor Bio raises $150 million in private placement to fund clinical trials | 1 | Investing.com | ||
| 15.12.25 | Vor Bio announces $150M private placement | 5 | Seeking Alpha | ||
| 15.12.25 | Vor Biopharma: Vor Bio Announces $150 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 09.12.25 | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential | 17 | Investing.com | ||
| 09.12.25 | JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target | 6 | Investing.com | ||
| 13.11.25 | Vor Biopharma: Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 448 | GlobeNewswire (Europe) | Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected... ► Artikel lesen | |
| 12.11.25 | Vor Biopharma Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.11.25 | Vor Biopharma Stock Sinks 48% | 9 | RTTNews | ||
| 11.11.25 | Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial | 12 | Benzinga.com | ||
| 11.11.25 | Vor Biopharma slumps 26%, prices $100M equity at $10 per share | 1 | Seeking Alpha | ||
| 11.11.25 | Vor Biopharma Prices Public Offering Of 10 Mln Shares At $10.00/shr | 3 | RTTNews | ||
| 11.11.25 | Vor Bio prices $100 million public offering of common stock | 6 | Investing.com | ||
| 11.11.25 | Vor Biopharma: Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock | 336 | GlobeNewswire (Europe) | BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the... ► Artikel lesen |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 48,200 | -1,23 % | Forget CRISPR Therapeutics: This Gene-Editing Player Already Boasts the Profits It Dreams Of | ||
| EDITAS MEDICINE | 1,650 | -4,52 % | Editas Medicine: Strategischer Fokus auf In-vivo-CRISPR-Therapie | ||
| GERON | 1,282 | -3,10 % | GERON CORP - 10-K, Annual Report | ||
| SOL GLOBAL INVESTMENTS | 0,051 | -2,86 % | SOL Global Investments Corp.: SOL Global Announces Leadership Transition and Grant of PSUs | Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), today announced that Mr. Davide Marcotti has resigned... ► Artikel lesen | |
| TRINITY BIOTECH | 0,735 | -0,38 % | Trinity Biotech plc: Trinity Biotech Secures $25 Million Financing Commitment to Support Growth Initiatives | - Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company's ambitions to expand its commercialisation activities and advance its innovation... ► Artikel lesen | |
| FATE THERAPEUTICS | 1,235 | +7,39 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| ARCTURUS THERAPEUTICS | 7,130 | -1,66 % | Demystifying Arcturus Therapeutics: Insights From 4 Analyst Reviews | ||
| OVID THERAPEUTICS | 1,730 | +4,85 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer | NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,... ► Artikel lesen | |
| CERVOMED | 3,560 | +1,14 % | CervoMed Inc.: CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies | Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new,... ► Artikel lesen | |
| EQUILLIUM | 1,432 | +1,27 % | Equillium, Inc.: Equillium Announces Leadership and Corporate Updates | LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics... ► Artikel lesen | |
| CABALETTA BIO | 3,150 | -1,10 % | Cabaletta Bio-Aktie: Wird sie 2026 erneut zum Biotech-Highflyer? | Die Aktie des ehemaligen sharedeals.de-Tenbaggers Cabaletta Bio wird seit geraumer Zeit wieder mit vorsichtigem Optimismus begleitet, während das Biotech-Unternehmen versucht, eine gentechnisch veränderte... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 8,490 | -1,62 % | 4D Molecular Therapeutics, Inc.: 4DMT Provides Company Update and Anticipated Development Milestones for 2026 | Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 23,710 | -2,83 % | Don't Even Think About Buying Regencell Bioscience Stock Until You See This 1 Red Flag | ||
| THX PHARMA | 3,180 | +1,60 % | THERANEXUS: THX Pharma Reports Its Cash Position as of December 31, 2025 | Lyon, France - February 19, 2026, 6:00 p.m. CET - THX Pharma (Theranexus), an innovative biopharmaceutical company specializing in the treatment of rare neurological diseases, today announces... ► Artikel lesen | |
| LONGEVERON | 0,484 | -2,52 % | Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell | MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,110 Euro und damit +3,99 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.